Dr. Beam has led venture capital investments in more than 25 life science and technology companies in the areas of therapeutics, enabling technologies, and diagnostics and also supports a number of strategic corporate initiatives. She supports Alexandria’s west coast operations by providing scientific expertise and insights on the life science and technology sectors. She is responsible for venture investment, business development, and tenant underwriting in Alexandria’s San Francisco Bay Area and Seattle cluster locations through the company’s strategic venture investment arm, Alexandria Venture Investments. Dr. Beam represents Alexandria as a Board Observer for DiCE Molecules, BioGraph 55, and TwinStrand Biosciences.
Prior to joining Alexandria, Dr. Beam was Vice President at Square 1 Bank, where she worked closely with early-stage, venture-backed life science and technology companies and venture capitalists to structure, underwrite, and monitor debt transactions. She earned her Doctor of Philosophy degree in Biomedical Engineering from Northwestern University and her Bachelor of Science degree in Chemical Engineering from Stanford University. Dr. Beam’s research and publications have focused on the fields of protein misfolding, neurodegenerative disease, biochemistry, and florescence-based imaging techniques.